• Hamlet BioPharma will hold its annual general meeting at High Court in Malmö on November 20, 2026.
• Shareholders will vote on authorizing share, warrant and/or convertible issuance totaling up to 10% of registered shares when the authorization is first used.
• The authorization would run until the next annual meeting, allowing issuance without shareholder preemptive rights to support financing, broaden ownership or enable acquisitions.
• The board proposes no dividend for fiscal 2025/2026, with the result carried forward.
• Major shareholders propose reelecting all four board members, retaining Catharina Svanborg as chair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610230300BITN____UKPR__SV_20261021-BIT-7871-0) on October 23, 2026, and is solely responsible for the information contained therein.